104 related articles for article (PubMed ID: 38476610)
41. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
42. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling.
Zhong Q; Fang Y; Lai Q; Wang S; He C; Li A; Liu S; Yan Q
J Exp Clin Cancer Res; 2020 Jul; 39(1):132. PubMed ID: 32653013
[TBL] [Abstract][Full Text] [Related]
43. Visualizing and interpreting cancer genomics data via the Xena platform.
Goldman MJ; Craft B; Hastie M; Repečka K; McDade F; Kamath A; Banerjee A; Luo Y; Rogers D; Brooks AN; Zhu J; Haussler D
Nat Biotechnol; 2020 Jun; 38(6):675-678. PubMed ID: 32444850
[No Abstract] [Full Text] [Related]
44. TIMER2.0 for analysis of tumor-infiltrating immune cells.
Li T; Fu J; Zeng Z; Cohen D; Li J; Chen Q; Li B; Liu XS
Nucleic Acids Res; 2020 Jul; 48(W1):W509-W514. PubMed ID: 32442275
[TBL] [Abstract][Full Text] [Related]
45. TIM3 comes of age as an inhibitory receptor.
Wolf Y; Anderson AC; Kuchroo VK
Nat Rev Immunol; 2020 Mar; 20(3):173-185. PubMed ID: 31676858
[TBL] [Abstract][Full Text] [Related]
46. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
47. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
[TBL] [Abstract][Full Text] [Related]
48. Restriction of PD-1 function by
Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
[TBL] [Abstract][Full Text] [Related]
49. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species.
Zilionis R; Engblom C; Pfirschke C; Savova V; Zemmour D; Saatcioglu HD; Krishnan I; Maroni G; Meyerovitz CV; Kerwin CM; Choi S; Richards WG; De Rienzo A; Tenen DG; Bueno R; Levantini E; Pittet MJ; Klein AM
Immunity; 2019 May; 50(5):1317-1334.e10. PubMed ID: 30979687
[TBL] [Abstract][Full Text] [Related]
50. Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment.
Cheng HS; Lee JXT; Wahli W; Tan NS
Mol Cancer; 2019 Mar; 18(1):51. PubMed ID: 30925918
[TBL] [Abstract][Full Text] [Related]
51. Neoantigen-directed immune escape in lung cancer evolution.
Rosenthal R; Cadieux EL; Salgado R; Bakir MA; Moore DA; Hiley CT; Lund T; Tanić M; Reading JL; Joshi K; Henry JY; Ghorani E; Wilson GA; Birkbak NJ; Jamal-Hanjani M; Veeriah S; Szallasi Z; Loi S; Hellmann MD; Feber A; Chain B; Herrero J; Quezada SA; Demeulemeester J; Van Loo P; Beck S; McGranahan N; Swanton C;
Nature; 2019 Mar; 567(7749):479-485. PubMed ID: 30894752
[TBL] [Abstract][Full Text] [Related]
52. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
[TBL] [Abstract][Full Text] [Related]
53. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
54. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
[TBL] [Abstract][Full Text] [Related]
55. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
[TBL] [Abstract][Full Text] [Related]
56. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.
Klepsch V; Hermann-Kleiter N; Do-Dinh P; Jakic B; Offermann A; Efremova M; Sopper S; Rieder D; Krogsdam A; Gamerith G; Perner S; Tzankov A; Trajanoski Z; Wolf D; Baier G
Nat Commun; 2018 Apr; 9(1):1538. PubMed ID: 29670099
[TBL] [Abstract][Full Text] [Related]
57. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
58. Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.
Masugi Y; Nishihara R; Hamada T; Song M; da Silva A; Kosumi K; Gu M; Shi Y; Li W; Liu L; Nevo D; Inamura K; Cao Y; Liao X; Nosho K; Chan AT; Giannakis M; Bass AJ; Hodi FS; Freeman GJ; Rodig SJ; Fuchs CS; Qian ZR; Nowak JA; Ogino S
Cancer Immunol Res; 2017 Nov; 5(11):1046-1055. PubMed ID: 29038297
[TBL] [Abstract][Full Text] [Related]
59. Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation.
Togashi Y; Nishikawa H
Curr Top Microbiol Immunol; 2017; 410():3-27. PubMed ID: 28879523
[TBL] [Abstract][Full Text] [Related]
60. Cancer Evolution Constrained by the Immune Microenvironment.
McGranahan N; Swanton C
Cell; 2017 Aug; 170(5):825-827. PubMed ID: 28841415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
